Tocovid SupraBio联合己酮可可碱治疗盆腔肿瘤放疗后长期胃肠道不良反应的随机单中心双盲安慰剂对照II期试验:PPALM研究
这项随机单中心双盲安慰剂对照II期试验纳入62例盆腔肿瘤放疗后长期胃肠道症状患者,随机接受Tocovid SupraBio 200 mg联合己酮可可碱400 mg每日两次口服治疗一年(40例)或匹配安慰剂(22例)。结果显示胃肠道症状评分及生活质量均无改善,但治疗期间EGF、PDGF、FGF水平显著降低且抗炎趋势一致,治疗结束后未维持。
要点
- 62例盆腔放疗后长期胃肠道症状患者随机接受联合治疗或安慰剂,症状评分及生活质量均无改善。
- 治疗期间EGF、PDGF、FGF水平显著降低且抗炎趋势一致,但治疗结束后未维持。
- 发生13例严重不良事件,其中1例短暂性脑缺血发作可能与己酮可可碱相关。
核心结论
- 本研究因提前终止而数据解释受限,未显示临床获益。
- 生化数据提示该干预具有抗炎和抗纤维化效应。
研究设计与样本
- 随机单中心双盲安慰剂对照II期试验,纳入62例盆腔肿瘤放疗后长期胃肠道不良反应患者,按症状严重程度分层随机。
- 40例(65%)随机至Tocovid SupraBio 200 mg联合己酮可可碱400 mg每日两次口服治疗一年,22例(35%)随机至匹配安慰剂,放疗完成后中位39个月入组。
- 主要终点为采用炎症性肠病问卷肠道子集评分评估的胃肠道症状改善,并评估纤维化生物标志物变化。
主要发现
- 62例患者中位年龄66岁,34例(55%)为前列腺癌,21例(34%)为妇科肿瘤,6例(10%)为肛管癌,1例(1%)为直肠癌。
- 治疗组41%患者血清中未检测到γ-生育三烯酚,尽管研究药物依从性良好。
- 治疗组28例(70%)和安慰剂组17例(77%)完成治疗。
- 症状评分及生活质量均无改善。
- 治疗期间EGF、PDGF、FGF水平显著降低且抗炎趋势一致,但治疗结束后未维持。
局限性
- 本研究为单中心研究且提前终止,数据解释必然受限。
- 治疗组41%患者血清中未检测到γ-生育三烯酚,尽管研究药物依从性良好。
- 发生13例严重不良事件,其中1例短暂性脑缺血发作可能与己酮可可碱相关,其余评估为不太可能与治疗相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical data suggest that combined gamma-tocotrienol with pentoxifylline ameliorates radiotherapy-induced gastrointestinal damage. AIM: To test whether gastrointestinal symptoms arising after radiotherapy, and persisting after maximal medical therapy, can be improved using Tocovid SupraBio 200 mg and pentoxifylline 400 mg orally twice daily for one year. Patients stratified by severity of symptoms, and randomised to active treatment or matched placebo were assessed after 12 months. The primary end point was improvement in gastrointestinal symptoms measured using the Inflammatory Bowel Disease Questionnaire, bowel subset score. Changes in bio-markers of fibrosis were assessed. RESULTS: 62 patients, median age 66, 34(55%) treated for prostate, 21(34%) gynaecological, 6(10%) anal and one(1%) rectal cancer were recruited; 40(65%) randomised to treatment, 22(35%) to placebo, 39 months (median) after radiotherapy completion. Gamma tocotrienol was not detected in serum in 41% of treated patients, despite good compliance with study medication. Treatment was completed in 28(70%) and 17(77%) patients in the treatment and placebo groups respectively. No improvement in symptom scores nor in quality of life was identified. Thirteen serious adverse events occurred. A transient ischaemic attack, was possibly related to pentoxifylline, others were assessed as unlikely to be related to treatment. Levels of EGF, PDGF and FGF were significantly reduced and consistent trends in reduced inflammation were seen during treatment but were not sustained once treatment ended. SUMMARY: This single centre study closed prematurely and therefore data interpretation is of necessity limited. No clinical benefit was demonstrated. However, biochemical data suggest that this intervention does have anti-inflammatory and anti-fibrotic effects.
引用
- Andreyev HJN, Matthews J, Adams C, et al. Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study. Radiother Oncol. 2022. PMID: 35093409. doi:10.1016/j.radonc.2022.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。